Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selegiline plus Docetaxel in metastatic castrate-resistant prostate cancer
NCT04586543Phase 2Unknown
- Start
- May 2020
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selegiline in prostate adenocarcinoma. Status: unknown.
02
Drugs
selegiline
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT04586543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586543.